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Abstract: 33 
Background: Hippocampal atrophy is presumably one morphological sign of critical illness 34 
encephalopathy, however predictors have not yet been determined. 35 
Methods: The data for this report derived from patients treated at the intensive care units of 36 
the University Hospital in Bonn in the years 2004-2006. These patients underwent structural 37 
magnetic resonance imaging 6-24 months after discharge. Volumes (intracranial, whole 38 
brain, white matter, grey matter, cerebral spinal fluid, bilateral hippocampus) were compared 39 
to healthy controls. Pro-inflammatory parameters and ICU scoring systems were explored in 40 
conjunction with brain volumes. Cut-scores were defined to differentiate patients with high 41 
from those with low inflammatory response.   42 
Results: Hippocampal and white matter volume were reduced in critically ill patients 43 
compared to healthy controls. Procalcitonin showed a very strong correlation (r=-.903, p=.01) 44 
and interleukin-6 a moderate correlation with hippocampal volume (r=-.538, p=.031), but not 45 
with other brain volumes. C-reactive protein was linked to grey matter volume. There was no 46 
correlation with systemic inflammatory response syndrome (SIRS) criteria (body 47 
temperature, heart rate, respiratory rate, white blood cell count) neither for hippocampal nor 48 
whole brain volume. Furthermore, parameters representing severity of disease (APACHE II 49 
score, SOFA score, duration of stay, and duration of mechanical ventilation) were not 50 
associated with hippocampal or other brain volumes.  51 
Conclusions: This analysis suggests that high levels of procalcitonin and interleukin-6 in 52 
blood serum of critically ill patients are associated with a high likelihood of hippocampal 53 
atrophy irrespective of severity of disease measured by ICU scoring systems and other 54 
inflammatory parameters. 55 
56 
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Introduction 57 
It has been well established that critically ill patients often face acute brain dysfunction and 58 
even long-lasting impairment of the central nervous system, however the underlying 59 
mechanisms are still not completely understood [1–3]. The terminology of brain dysfunction 60 
in critical illness is not standardized. It is usually described as “encephalopathy”, “delirium”, 61 
or summarised as “neurobehavioural changes in critical illness”. According to the 62 
inflammatory hypothesis, acute systemic inflammation and subsequent increased production 63 
of inflammatory mediators lead to an alteration of the blood brain barrier and ultimately to 64 
neurodegeneration and neuroglial cell death [4–6]. Abnormalities in brain imaging are found 65 
in a high percentage (64%) of critically ill patients, most commonly atrophy [7,8]. The 66 
hippocampus is one of the most vulnerable parts of the brain and is highly susceptible to 67 
ischemia and hypoxia and chronic inflammation [9]. Persistent hippocampal atrophy was 68 
found in a sample of sepsis survivors long after ICU discharge [3]. Further, hippocampal 69 
atrophy is a salient feature of post traumatic stress disorder [10], Major Depression [11] and, 70 
in particular, Alzheimer’s disease, which may substantially be driven by systemic 71 
inflammation [5]. There is also epidemiological evidence indicating a connection between 72 
inflammation and brain MRI findings [13,14], however, to the authors’ knowledge there have 73 
been no studies investigating role of serum biomarkers to predict hippocampal volume 74 
deficits in critically ill patients.  The objective of this retrospective study was to identify 75 
predictors of hippocampal atrophy in critically ill patients among routinely assessed markers 76 
for inflammation including Systemic Inflammatory Response Syndrome (SIRS) criteria (body 77 
temperature, heart rate, respiratory rate, white blood cell count), C-reactive protein (CRP), 78 
procalcitonin (PCT), interleukin-6 (IL-6) and ICU scoring systems (Sequential Organ Failure 79 
Assessment=SOFA, Acute Physiology and Chronic Health score=APACHE II). 80 
 81 
Methods 82 
Design 83 
This study protocol was approved by the local Ethics Committee (Ethikkommission an der 84 
Medizinischen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn; approval 85 
Number 05/04) and written informed consent was obtained from all participants prior to 86 
testing. Twenty general critically ill patients (11m, 9f) who were treated in the years 2002–87 
2005 at the ICU of the University Hospital in Bonn were included. This represents a subset of 88 
patients from a larger study of critically ill patients published previously for whom we were 89 
able to obtain routine serum-biomarker data from patient files [3]. Inclusion criteria were ICU 90 
patients seen at the operative (anaesthesiological, surgical and cardiothoracic surgery) ICUs 91 
at the University of Bonn, the Department of Anaesthesiology and at the ICU of the Helios 92 
Clinic in Siegburg, Germany, between 2004 and August 2006. Exclusion criteria were history 93 
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of neurological disease (stroke, dementia, and cerebral trauma) or other diseases that might 94 
confound outcome measures (e.g., renal failure or hepatic insufficiency) as well as having 95 
undergone cardiopulmonary bypass surgery prior to ICU admission.  Initial diagnoses 96 
included pancreatitis (n=4), aorto-coronary-venous-bypass (n=5), non-head trauma (n=5), 97 
pneumonia (n=2), meningitis (n=1), abdominal aortic aneurysm (n=1), intestinal surgery 98 
(n=2). Other clinical and demographic data are listed in Tables 1a and 1b. These patients 99 
underwent MRI scans 6 to 24 months after discharge with hippocampus, whole brain, white 100 
matter, and grey matter as regions of interest. A healthy, sex-matched control group taken 101 
from an existing database was used for comparison (n=15m, 15f). Parameters entered into 102 
the analysis included: age, sex, weight, diagnosis, the Systemic Inflammatory Response 103 
Syndrome (SIRS) criteria body temperature, heart rate, respiratory rate, white blood cell 104 
count, the serum markers CRP, IL-6, PCT, the ICU scorings APACHE II, SOFA, duration of 105 
mechanical ventilation and duration of stay.  106 
 107 
Magnetic resonance imaging  108 
MR scanning of the patient groups was performed on three scanners with two magnetic field 109 
strengths (Tesla 1.5 and Tesla 3). Scanning of healthy controls in the database was done 110 
with a Philips 1.5TAchieva whole body system. For all groups, a 3D FFE sequence 111 
(TE/TR/FLIP: 15/3.6 mesc/30°) was acquired with 140 slices and a resolution of 1×1×1 mm3.  112 
 113 
Brain Volumetry 114 
Data were converted to the analyze-format and brain volumetry was manually performed 115 
using Analyse 7.0 software, according to a previously published protocol [15]. The intra-rater 116 
reliability was assessed by blindly measuring 10 independent test MR volumes. The intra-117 
rater correlation coefficient of 10 independent MRI data sets, which were measured twice 118 
blindly by the same rater was r = 0.98.  Hippocampal volumes were manually traced on these 119 
images. Intracranial volumes were obtained by automated tissue segmentation with SPM5 120 
(Wellcome Department of Cognitive Neurology, London) using tissue probability maps. The 121 
volumes of hippocampi were divided by the total intracranial volume to adjust for differences 122 
in head size. 123 
 124 
Statistical analysis 125 
Statistical analysis was performed using IBM SPSS 20.0. Bivariate Spearman correlations 126 
were used for clinical variables. Multivariate Analysis of Covariance (MANCOVA) was used 127 
to compare brain volumetry using age and intracranial volume as covariates. For statistical 128 
analysis subgroups were defined using cut-scores to differentiate ICU patients with 129 
hippocampal volumes above and below -1 SD of the mean in the control group. High and low 130 
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inflammatory responses were: PCT>2ng/ml, IL-6>500pg/ml and CRP>100mg/l [16,17,18]. 131 
Cut-scores of SOFA score above 11 points and APACHE II score above 24 points, which 132 
indicate severe critical illness, were used for analysis. Area under the receiver operating 133 
characteristic (ROC) curve analyses and exact 2-sided Mann-Whitney-U-tests were used for 134 
these artificially discrete serum marker and score data. Linear regression analyses were 135 
conducted to determine how much variance in hippocampal volume could be explained by 136 
levels of inflammation. For all comparisons, the alpha level was set at 5%. 137 
 138 
Results 139 
Demographic and clinical characteristics are shown in table 1a. The total hippocampal 140 
volume and white matter were both reduced in critically ill patients compared to healthy 141 
controls, even after correcting for differences in age and intracranial volume (table 1b). 142 
Among blood serum markers, PCT showed a strong correlation with hippocampal volume 143 
(r=-.903, p=.01). Interleukin-6 was moderately associated with hippocampal volume (r=-.538, 144 
p=.031), but neither marker was associated with any other brain volume measure 145 
(intracranial, whole brain, grey matter, white matter, CSF). Individual SIRS-criteria 146 
(temperature, heart rate, respiratory rate or white blood cell count) did not correlate with brain 147 
volumes (data not shown). Furthermore, clinical scores and parameters of severity of critical 148 
illness such as APACHE II (r=-.072, p=n.s.) or SOFA score (r=-.273, p=n.s.), duration of stay 149 
(r=-.137, p=n.s.) and mechanical ventilation (r=-.248, p=n.s.) did not correlate with any brain 150 
volume. There was no link between SOFA score or APACHE II score to brain volume using 151 
either MWU or ROC analysis (data not shown).  152 
 153 
Table 1a,b,c,d around here. 154 
 155 
High levels of PCT (MWU=.000, p=.016) and IL-6 (MWU=3.000, p=.002; Figure 1a,b) 156 
indicated lowered hippocampal volume. Furthermore, there was no dependence of 157 
intracranial, whole brain, white or grey matter on IL-6 or PCT (data not shown). Higher levels 158 
of CRP predicted reduced grey matter (MWU=.4000, p=.018), but this was not the case for 159 
any other brain volume analysed (data not shown). In addition, ROC analysis showed large 160 
areas under the curve for high levels of PCT>.13ng/ml (AUC=.729) and hippocampal 161 
volume, grey matter (AUC=.803) and whole brain volume (AUC=.718). Linear regression 162 
analyses (Table 1d) indicate that 62% of adjusted variance of total hippocampal volume can 163 
be explained by level of PCT alone; 70.8% can be explained by level of PCT and IL-6 164 
together. The further addition of CRP to the regression model only added an insignificant 165 
amount of predictive power. Of note, there was a high level of collinearity between the first 166 
two predictors.  167 
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Figure 1a,b around here. 169 
 170 
Discussion 171 
Brain integrity appears to be vulnerable to systemic inflammation during critical illness, which 172 
is consistent with findings of induced sepsis in rats [19,20] and recent neuroimaging findings 173 
of survivors of critical illness [8]. The VISIONS study of a convenience sample of ICU 174 
survivors (47 patients, mean age 58 years) found reductions in hippocampal and frontal lobe 175 
volumes, although they did not study serum biomarkers. Instead, they found an association 176 
with duration of delirium, which was not predicted by severity of illness as measured by 177 
SOFA score [12]. Systemic inflammation is one important driver of delirium [21]. This 178 
analysis suggests that a high level of inflammation in critically ill patients measured by high 179 
serum levels of PCT, IL-6 and CRP may imperil the brain, and particularly the hippocampus, 180 
irrespective of the severity of critical illness measured in ICU scoring systems, duration of 181 
mechanical ventilation or duration of ICU stay.  182 
Furthermore, two large epidemiologic studies also support a connection between 183 
inflammation and brain MRI findings. The 3C-Dijon Study (1,316 participants, mean age 72 184 
years) found that IL-6 and, to a lesser, degree CRP are associated with hippocampal and 185 
grey matter volume [13]. Findings from the Framingham Heart Study (1,926 participants, 186 
mean age 60.4 years) indicate that higher levels of inflammatory markers including IL-6 and 187 
CRP are associated with greater brain atrophy [14]. The serum marker PCT was not 188 
measured in these studies. Our results are in line with these findings. To our knowledge this 189 
is the first analysis comparing PCT, IL-6, CRP and brain volume in a sample of critically ill 190 
patients.  191 
Our derived cut-scores for these three serum biomarkers are far lower than that found in the 192 
literature indicating high inflammatory response. Hence, these cut-scores may be useful only 193 
for predicting brain atrophy only in the studied population.  The generalisability of this study is 194 
limited by its sample size, the lack of pre-morbid brain scans, socioeconomic data, as well as 195 
actively recruited healthy controls and retrospective nature. Additionally, critically ill patients 196 
are individuals encountering various, complex and alternating experiences and varied 197 
durations between ICU stay and follow-up, which were not controlled for. Whether brain 198 
atrophy is a direct result of or a secondary event cannot be concluded based on this study. 199 
The contribution of other factors such as hypoxia, dehydration, electrolytic imbalance and 200 
pharmacological agents cannot be excluded. Nonetheless, PCT, and, to a lesser degree, IL-201 
6 and CRP may help to identify critically ill patients at risk for brain damage who might 202 
benefit from neuroprotective intervention. A potential target would be to control the individual 203 
inflammatory response in critically ill patients. However, since inflammation also plays a 204 
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protective role and promotes regeneration of damaged neurons, it might be quite challenging 205 
to achieve “balanced” inflammation. The next step would be to conduct a prospective study 206 
with a larger cohort to explore the effects of critical illness and inflammation markers on the 207 
brain. Future directions would include further neuroimaging research, interventions during 208 
ICU stay and rehabilitative interventions after critical illness.  209 
 210 
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Table and Figure Titles and Captions:  302 
 303 
Table1a. Demographic and clinical characteristics critically ill 304 
 N Minimum Maximum Mean SD 
Age (years) 20 20 77 52.2 16.29 
Weight (kg) 20 55 110 80.2 13.14 
Duration of 
stay (days) 
 
20 1 74 18.6 22.59 
Duration of 
mechanical 
ventilation 
(days) 
 
19 0 69 12.3 18.71 
APACHE II  18 10 33 18.2 6.43 
SOFA 17 1 14 6. 2 3.91 
PCT max. 
(pg/ml) 
 
10 0.069 24.7 4.9 7.56 
IL-6 max.  
(ng/ml) 
 
16 25 41195 4062.7 10427.90 
CRP max. 
(mg/l)  
15 2 364 171.7 113.47 
 305 
Table1a. Demographic and clinical characteristics critically ill 306 
 307 
PCT max. = Procalcitonin maximum value during ICU stay; IL-6 max. = Interleukin-6 308 
maximum value during ICU stay; CRP max. = CRP maximum value during ICU stay; 309 
APACHE II = Acute Physiology and Chronic Health score; SOFA = Sequential Organ Failure 310 
Assessment.  311 
312 
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Table 1b. Brain volumetry results of univariate tests of MANCOVA with covariates age and 313 
intracranial volume 314 
 Healthy Controls 
(n = 30) 
Critically Ill 
(n = 19) 
  
 Mean SD Mean SD F Sign. 
Age (years)* 40.3 10.31 52.2 16.29 - - 
Total 
intracranial 
volume (ml)* 
 
1622.63 156.76 1568.53 185.92 - - 
Whole brain 
volume (ml) 
 
1214.19 126.50 1118.56 102.29 3.165 .082 
Grey Matter 
(ml) 
716.54 75.98 667.25 67.49 .146 .704 
White Matter 
(ml) 
497.66 67.17 451.31 47.50 6.219 .016 
CSF (ml) 408.43 89.15 449.96 130.43 3.165 .082 
Hippocampal 
volume (ml) 
5.56 .11 5.22 .61 5.684 .021 
 315 
 316 
Table 1b. Brain volumetry results of univariate tests of MANCOVA 317 
 318 
Healthy controls were taken from an existing database for purposes of comparison of brain 319 
volumes only. There was a positive result in multivariate testing for age (Wilks-Lambda = 320 
.757, F(3.43) = 4.591, p = .007) for intracranial volume (Wilks-Lambda = .369, F(3.43) = 24.527, 321 
p = .000) and for critical illness (Wilks-Lambda = .243, F(3.43) = 3.487, p = .024). Univariate 322 
results are reported here.  323 
 324 
325 
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Table 1c. ROC-Analysis for area under the curve for serum biomarkers predicting reduced 326 
brain volumes 327 
Optimal cut-
score 
Hippocampus 
< -1SD below 
norm 
Grey Matter 
< -1SD below 
norm 
White Matter 
< -1SD below 
norm 
Whole Brain 
< -1SD below 
norm 
PCT > .13 pg/ml .729 .803 .694 .718 
IL-6 > 24.4 ng/m .382 .474 .416 .436 
CRP > 10.6 mg/l .263 .404 .304 .315 
 328 
Table 1c. Brain volumetry results or ROC-Analysis for area under the curve 329 
 330 
Note: These results show how well the serum biomarkers PCT, IL-6 and CRP can identify 331 
patients with brain volumes (hippocampus, whole brain, grey matter and white matter) that 332 
are less than -1 SD below the mean in the control group.  333 
 334 
 335 
 336 
 337 
 338 
 339 
Table 1d. Multiple regression analysis summary serum biomarkers predicting total 340 
hippocampal volume 341 
Model R Adjusted R2 ∆ R2 
1. .830a .688 .688* 
2. .897b .805 .117 
3. .937c .878 .073 
a Predictor: constant, PCT >2 pg/ml 342 
b Predictor: constant, PCT >2 pg/ml , IL-6 >500 ng/m 343 
c Predictor: constant, PCT >2 pg/ml , IL-6 >500 ng/m, CRP >100 mg/l 344 
Dependent variable: total hippocampal volume 345 
* p < .05 346 
 347 
  348 
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 349 
 350 
Figure 1a. MRI Scan (3-Tesla) showing left hippocampal atrophy, indicated by the arrow. 351 
Scans are shown according to radiologic convention.  352 
 353 
 354 
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Figure 1b. Box plots of hippocampal volume for those with high and low inflammatory 355 
responses designated according to the following cut-scores: PCT< 2 ng/ml = low 356 
inflammation; PCT ≥ 2 ng/ml = high inflammation; IL-6 < 500 pg/ml = low inflammation. IL-6 ≥ 357 
500 pg/ml = high inflammation. *p < .05. **p < .01 358 
359 
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 360 
Fig 1c 361 
362 
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 363 
Fig 1d 364 
365 
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 366 
 367 
Fig 1e 368 
 369 
 370 
Fig 1f 371 
 372 
Figures 1c-f. Receiver Operator Characteristic graphs showing PCT, IL-6 and CRP as 373 
predictors of c) hippocampal volume -1SD below mean of the control group, d) whole brain 374 
volume -1SD below mean of the control group, e) grey matter volume -1SD below mean of 375 
the control group and f) white matter volume -1SD below mean of the control group. 376 
